Skip to search formSkip to main contentSkip to account menu

Cancer and Leukemia Group B

Known as: CALGB 
A national clinical research group - network of 29 university medical centers, over 185 community hospitals and more than almost 3000 physicians… 
National Institutes of Health

Related topics

Related topics

1 relation
Source of protocol in which patient enrolled:Type:Pt:Cancer.XXX:Nom

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Initial results of CALGB 80803 (Alliance): A randomized phase II trial of PET scan-directed combined modality therapy for esophageal cancer.
1Background: To determine whether changing chemotherapy (CT) during pre-op chemoradiation (CRT) based on response to induction CT… 
Highly Cited
2014
Highly Cited
2014
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).
PURPOSE Optimal adjuvant chemotherapy for early-stage breast cancer balances efficacy and toxicity. We sought to determine… 
Highly Cited
2013
Highly Cited
2013
Abstract S5-01: Impact of the addition of carboplatin (Cb) and/or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple…
Background: Anthracycline- and taxane-based neoadjuvant chemotherapy (NAC) results in a pCR in 30-35% of TNBC patients (pts… 
Highly Cited
2002
Highly Cited
2002
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011…
HeadingAbstractPurpose. Fludarabine is a renally excreted agent that is an effective treatment for chronic lymphocytic leukemia… 
Highly Cited
2000
Highly Cited
2000
CALGB Study 9431: A randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy (Ind CT) and concomitant chemoradiotherapy (XRT) for unresectable…
Highly Cited
2000
Highly Cited
2000
Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013.
PURPOSE Recombinant interferon alfa-2b (rIFNalpha2b) is a standard therapy for chronic myelogenous leukemia (CML). Severe… 
1999
1999
Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study.
The topoisomerase I inhibitor topotecan had demonstrated good antitumor activity in several murine tumor systems and in human… 
Review
1994
Review
1994
Audit of Cancer and Leukemia Group B data.
To the Editor: One of the cases reported in our paper “Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node… 
Highly Cited
1987
Highly Cited
1987
Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B.
Three combination chemotherapy regimens each with or without the methanol-extracted residue of bacillus Calmette-Guérin (BCG… 
1986
1986
Single, sequential, and multiple alkylating agent therapy for multiple myeloma: a CALGB Study.
Four intravenous (IV) alkylating agent regimens were tested in 615 previously untreated patients with multiple myeloma. Patients… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)